Envestnet Asset Management Inc. Has $232.44 Million Holdings in AstraZeneca PLC (NASDAQ:AZN)

Envestnet Asset Management Inc. lifted its holdings in shares of AstraZeneca PLC (NASDAQ:AZN) by 0.8% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 3,547,564 shares of the company’s stock after buying an additional 29,771 shares during the quarter. Envestnet Asset Management Inc. owned about 0.11% of AstraZeneca worth $232,436,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also modified their holdings of AZN. Arete Wealth Advisors LLC boosted its holdings in AstraZeneca by 98.3% during the fourth quarter. Arete Wealth Advisors LLC now owns 8,474 shares of the company’s stock worth $555,000 after buying an additional 4,200 shares during the last quarter. World Investment Advisors boosted its stake in AstraZeneca by 3.6% during the 4th quarter. World Investment Advisors now owns 8,564 shares of the company’s stock worth $561,000 after acquiring an additional 297 shares during the last quarter. Martin Investment Management LLC grew its holdings in AstraZeneca by 8.5% during the fourth quarter. Martin Investment Management LLC now owns 308,489 shares of the company’s stock valued at $20,575,000 after purchasing an additional 24,285 shares during the period. OneAscent Financial Services LLC bought a new stake in AstraZeneca in the fourth quarter valued at approximately $232,000. Finally, Cinctive Capital Management LP raised its holdings in AstraZeneca by 88.4% in the fourth quarter. Cinctive Capital Management LP now owns 84,653 shares of the company’s stock worth $5,546,000 after purchasing an additional 39,718 shares during the period. 20.35% of the stock is owned by institutional investors.

AstraZeneca Price Performance

AZN stock opened at $68.46 on Monday. The stock has a market cap of $212.31 billion, a PE ratio of 30.29, a price-to-earnings-growth ratio of 1.42 and a beta of 0.49. The stock has a 50-day moving average price of $73.96 and a two-hundred day moving average price of $71.38. AstraZeneca PLC has a 1 year low of $62.75 and a 1 year high of $87.68. The company has a current ratio of 0.93, a quick ratio of 0.74 and a debt-to-equity ratio of 0.65.

AstraZeneca (NASDAQ:AZN) last announced its earnings results on Thursday, February 6th. The company reported $1.05 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.10 by ($0.05). AstraZeneca had a net margin of 13.01% and a return on equity of 32.23%. Equities analysts forecast that AstraZeneca PLC will post 4.51 EPS for the current fiscal year.

AstraZeneca Increases Dividend

The firm also recently announced a semi-annual dividend, which was paid on Monday, March 24th. Investors of record on Friday, February 21st were issued a dividend of $1.03 per share. This is a boost from AstraZeneca’s previous semi-annual dividend of $0.49. The ex-dividend date was Friday, February 21st. This represents a yield of 2%. AstraZeneca’s dividend payout ratio is presently 91.15%.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on the stock. UBS Group raised shares of AstraZeneca from a “neutral” rating to a “buy” rating in a report on Thursday, February 13th. Morgan Stanley began coverage on AstraZeneca in a research note on Wednesday, February 12th. They issued an “overweight” rating for the company. One research analyst has rated the stock with a hold rating, seven have issued a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Buy” and a consensus target price of $89.75.

AstraZeneca Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.